AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06104566
Drug: BTK inhibitor
RxNorm normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTK inhibitor
Trial: NCT06326086
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy drug as prescribed by primary treating physician
Trial: NCT04921969
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study cream will be applied topically twice a day for up to 52 weeks.
Trial: NCT06259149
Drug: Nardraparin calcium injection
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
Trial: NCT04959799
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
Trial: NCT05379595
Drug: Amivantamab
RxNorm normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Amivantamab will be administered as intravenous infusion.
Trial: NCT05177068
Drug: fruquintinib + sintilimab + SOX
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fruquintinib: 4mg/d, qd po, d1-14, q3w; sintilimab: 200 mg/d, IV d1, q3w; S-1: BSA\<1.25 m2, 40mg twice/day; BSA1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, d1-14, q3w; oxaliplatin: 130mg/m2, ivgtt 2-6h, d1, q3w
Trial: NCT04609020
Drug: BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Indicated for the treatment of hyperkinetic facial lines.
Trial: NCT05463497
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
Trial: NCT05463497
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C2104 : single administration, Tablet, Oral, QD for 5 days
Trial: NCT05463497
Drug: Treatment E
RxNorm normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
Trial: NCT05061147
Drug: MAX-40279-01
RxNorm normalized name: bimatoprost 0.01 MG
DrugBank: MAX-40279 (DB15191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: AZA AZA will be administered at 75 mg/m\^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.~Other Name: Azacitidine~Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.~Other Name: NA
Trial: NCT04814589
Drug: ezetimibe tablets
RxNorm normalized name: Ezetimibe Tablets
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
Trial: NCT04814589
Drug: ezetimibe tablets(Ezetrol ®)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
Trial: NCT04909515
Drug: Naxitamab
RxNorm normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.0 mg/kg/day = 9.0 mg/kg/cycle
Trial: NCT04909515
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 - 500 microgram/m2/day
Trial: NCT04909515
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 mg/m2/day
Trial: NCT05830890
Drug: Indocyanine green solution
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green was injected around the tumor via the anus to visualize the sentinel lymph nodes under the fluorescence laparoscope.
Trial: NCT05817955
Drug: Azacitidine (AZA) with Ruxolitinib
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture.
Trial: NCT06203483
Drug: Adductor canal block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.
Trial: NCT05065294
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
Trial: NCT05038449
Drug: Colchicine Tablets
RxNorm normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine Tablets (Each tablet contains colchicine 0.5mg)
Trial: NCT06700343
Drug: Ocrelizumab (US)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT06700343
Drug: Ocrelizumab (EU)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT06700343
Drug: ABP 692
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00063804
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04892199
Drug: Semaglutide, 1.34 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
Trial: NCT04892199
Drug: Semaglutide-placebo
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study.
Trial: NCT05976685
Drug: DOAC
RxNorm normalized name: Benzamidoacetic acid
DrugBank: Robinia pseudoacacia pollen (DB10474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
Trial: NCT05036798
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD
Trial: NCT06203483
Drug: PENG block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
Trial: NCT06319729
Drug: CDD-2105
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A Chinese herbal medicine formula containing four granular herbs.
Trial: NCT06710132
Drug: M9140
RxNorm normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.
Trial: NCT06361888
Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Trial: NCT06361888
Drug: Nab-paclitaxel Plus Gemcitabine
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Trial: NCT06361888
Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Trial: NCT06704152
Drug: SOC + BSB-1001 Dose Escalation Cohort
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).
Trial: NCT05105672
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05105672
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06704152
Drug: SOC+BSB-1001 Expansion Dose
RxNorm normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).
Trial: NCT05102071
Drug: empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: empagliflozin
Trial: NCT05102071
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin
Trial: NCT00609544
Drug: Rilonacept
RxNorm normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
Trial: NCT01499693
Drug: Magnesium Pantoprazole 20 mg
RxNorm normalized name: pantoprazole 20 MG
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dose, twice a day
Trial: NCT01499693
Drug: Magnesium Pantoprazole 40 mg
RxNorm normalized name: pantoprazole 40 MG
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dose, once a day (morning)
Trial: NCT05684289
Drug: BMS-986278
RxNorm normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05684289
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06008054
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion every 3 weeks (Q3W).
Trial: NCT06008054
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06008054
Drug: PD-1 Monoclonal Antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05607316
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily for the remainder of the study.
Trial: NCT04953741
Drug: Fluticasone propionate inhaled aerosol
RxNorm normalized name: Fluticasone Propionate Inhalation Aerosol
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
Trial: NCT06002659
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-conditioning chemotherapy
Trial: NCT06743126
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Trial: NCT06743126
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Trial: NCT06743126
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Trial: NCT06743126
Drug: paclitaxel plus carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Trial: NCT06743126
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Trial: NCT00037063
Drug: Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00037063
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04928144
Drug: SHJ - Low concentration
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic
Trial: NCT04928144
Drug: SHJ - High concentration
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic
Trial: NCT04928144
Drug: SHJ - Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SHJ - Maximum tolerated
Trial: NCT05785039
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05728333
Drug: Tirofiban
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tirofiban before endovascular thrombectomy.
Trial: NCT05728333
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase before endovascular thrombectomy.
Trial: NCT05460858
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.
Trial: NCT05462236
Drug: Tinodasertib
RxNorm normalized name: Tinodasertib
DrugBank: Tinodasertib (DB18796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNK inhibitor
Trial: NCT05462236
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 Inhibitor
Trial: NCT05462236
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topoisomerase inhibitor
Trial: NCT02567175
Drug: Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04877990
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05163106
Drug: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
Trial: NCT05163106
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
Trial: NCT06473116
Drug: Isoprenaline Only Product
RxNorm normalized name: Isoprenaline only product
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest
Trial: NCT04824937
Drug: Telaglenastat
RxNorm normalized name: Telaglenastat
DrugBank: Telaglenastat (DB15232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, taken by mouth
Trial: NCT04824937
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, taken by mouth